• Search
  • Advanced Search
Clin Mol Hepatol > Volume 31(3); 2025 > Article
Ahn, Tran, and Yang: Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]

Erratum

Clin Mol Hepatol. 2025; 31(3): 1103-1104.

Published online: July 1, 2025

DOI: https://doi.org/10.3350/cmh.2023.0051e

Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]

Joseph C. Ahn1, Nguyen H. Tran2, Ju Dong Yang3, 4, 5

Corresponding author : Ju Dong Yang Cedars-Sinai Medical Center, 8900 Beverly Blvd, Los Angeles, CA 90048, USA
Tel: +1-310-423-1971, Fax: +1-310-423-2356, E-mail: judong.yang@cshs.org

Copyright © 2025 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
There was an error in the table: “Phase III Trials of First-line Systemic Therapy for advanced HCC”
The PR for HIMALAYA (2022) trial was entered as 65.8% for Durva/Tre, 57.8% for Durva, and 63.2% for Sorafenib. However, those values actually refer to the proportion of patients remaining in response at 12 months.
The corrected PR values should be 17.0% for Durva/Tre, 15.4% for Durva, and 5.1% for Sorafenib.
After correction


cmh-2023-0051ef1.jpg
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 323 View
  • 5 Download
ORCID iDs

Ju Dong Yang
https://orcid.org/0000-0001-7834-9825

Related articles

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]2025 July;31(3)

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]2025 April;31(2)

Erratum to ‘Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction’ [Clin Mol Hepatol 2024;30:539-560]2024 October;30(4)

Erratum to ‘Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”’ [Clin Mol Hepatol 2023;29:1048-1049]2024 January;30(1)

Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]2023 July;29(3)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 2733
TOTAL : 2897235
Close layer